FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma.
The FLIPI24 calculates the probability (%) of event (progression, re-treatment, transformation, or death) within the first two years after starting frontline immunochemotherapy. The model assumes CD20 antibody plus CHOP or bendamustine based chemotherapy with a 50% likelihood of CD20 antibody maintenance. The model data are from the FLIPI24 Consortium, which is comprised of patient data from 10 international cohorts.
MJ Maurer et al,
The FLIPI24 calculates the probability (%) of event (progression, re-treatment, transformation, or death) within the first two years after starting frontline immunochemotherapy. The model assumes CD20 antibody plus CHOP or bendamustine based chemotherapy with a 50% likelihood of CD20 antibody maintenance. The model data are from the FLIPI24 Consortium, which is comprised of patient data from 10 international cohorts.
MJ Maurer et al,
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.
